Washington – A year after it was embroiled in scandal for jacking up the price of EpiPen injectors of a life saving anti-allergy medicine, the company that makes them is accused of overcharging state and federal governments, too, by $1.27 billion. Sen. Richard Blumenthal wants some of that money returned to Connecticut
Mylan
Posted inHealth, Politics
Trump attempt to rein in drug prices may have limited success
WASHINGTON – The president’s spokesman says Trump still favors a plan to negotiate Medicare prices, but he did not mention it after a recent meeting with pharmaceutical executives, and his plans to speed FDA approval of new drugs may be hampered by his restrictions on new regulations and cuts to the federal workforce.
Posted inHealth, Justice
Connecticut leads 20 states alleging price-fixing in generic drugs
Attorney General George Jepsen’s office is leading a multi-state investigation of generic drug companies that culminated Thursday in a federal price-fixing lawsuit filed in Hartford that complements an unfolding criminal antitrust investigation by the U.S. Department of Justice.
Posted inEducation, Health, Politics
Blumenthal calls for EpiPen antitrust probe
WASHINGTON – Sen. Richard Blumenthal on Tuesday asked the Federal Trade Commission to investigate whether EpiPen manufacturer Mylan broke anti-trust laws when it gave away or sold its product at discounted prices to schools.
Posted inHealth, Politics
EpiPen lobbying campaign targeted Connecticut
WASHINGTON – Connecticut, one of 11 states that approved a law requiring schools to stock EpiPens, is on drug maker Mylan’s sizable lobbying list. According to the center, Mylan, under fire for its steep price hikes of the EpiPen, expanded its lobbying presence in state houses to Connecticut and 35 additional states between 2010 to 2014.
Posted inHealth
A South Windsor native’s ‘pang of guilt’ touched off EpiPen war
Though her use of an online petition, Mellini Kantayya, touched off a furor over the rapid price hikes in the cost of EpiPens, the auto-injector that delivers a drug that counters the effects of a potentially fatal allergic reaction. She hopes the reaction will open the door to greater scrutiny of the pharmaceutical industry.